EPIX (ESSA Pharma) Research & Development: $12.62 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EPIX ESSA Pharma Inc EPIX
22 GF Score
Price $0.20
View Full Analysis

What is ESSA Pharma Research & Development?

ESSA Pharma EPIX 22 Research & Development is $12.62 Mil as of Jun. 2025. GuruFocus rates EPIX with a GF Score™ of 22/100.

Research & Development is the aggregate amount of research and development expenses during the year. ESSA Pharma's Research & Development for the three months ended in Jun. 2025 was $-0.53 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was $12.62 Mil.

ESSA Pharma  (NAS:EPIX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ESSA Pharma Research & Development Related Terms

ESSA Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for ESSA Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ESSA Pharma Research & Development Chart

ESSA Pharma Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.15 24.26 24.42 21.32 21.21

ESSA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.46 4.19 5.47 3.48 -0.53
EPIX
22GF Score
ESSA Pharma Inc EPIX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ESSA Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $12.62 Mil mean?
ESSA Pharma (EPIX) has a Research & Development of $12.62 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on ESSA Pharma and its competitors.
Is ESSA Pharma's Research & Development too high?
ESSA Pharma's current Research & Development is $12.62 Mil. Overall, ESSA Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does ESSA Pharma's Research & Development compare to SLXN and NLSP?
ESSA Pharma's Research & Development of $12.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ESSA Pharma and its competitors. ESSA Pharma's current Research & Development is $12.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ESSA Pharma stock overvalued right now?
ESSA Pharma (EPIX) has a current Research & Development of $12.62 Mil. The current Research & Development is $12.62 Mil. ESSA Pharma's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ESSA Pharma (EPIX), the current Research & Development is $12.62 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ESSA Pharma Business Description

Address 999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
22GF Score

Get the complete analysis for EPIX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price